myostatin inhibitor?

[peachfuzz]

Nolva and Clomid aren't chemotherapy drugs, they are drugs used to treat cancer. Go check what chemotherapy drugs are. Chemotherapy drugs destroy cells in the body (all types of cells).

I Know This

just trying to give you a hard time.

[Immortal Soldier]

BTW MYO-029 is no longer is trial. I think it got killed early 08

The reg public trials for any of the anti-bodies are not being conducted.

Earlier this month, the first human trials for myostatin inhibitors were published, revealing promising results. The study examined the effects of MYO-029, which is a recombinant human antibody that binds with a high affinity to myostatin and inhibits its activity.3 This myostatin-neutralizing antibody has previously been shown to increase muscle mass in mice by approximately 30 percent over three months.4 The study enrolled 136 subjects with various forms of muscular dystrophy. The subjects were randomized to three groups of MYO-029 dose escalation: group 1 received 1mg/kg; group 2 received 3mg/kg; and group 3 received 10mg/kg. Within each cohort, subjects were randomly assigned to receive the test drug or placebo. MYO-029 was administered intravenously every two weeks for six months (total of 13 doses). After the last dose, subjects were followed for three months. In this first-ever study of a myostatin inhibitor, the primary objective was safety. MYO-029 was well tolerated in the group of people with muscular dystrophies. No target-related side effects were identified to skeletal, smooth, or cardiac muscle. The most significant adverse events reported were skin reactions. Muscle mass was found to increase by approximately 2.4 percent in the 3mg/kg cohort; additionally there was a dose-dependent increase in fiber diameter in the 3 and 10mg/kg groups. The disappointing result of the study was that there were no increases in strength by the myostatin inhibitor. The myostatin drug seemed to have good tolerability at lower dosages, but at higher dosages many subjects experienced adverse skin reactions. The most exciting aspect of the study was that there were no adverse effects on the heart!

-Muscular Development June 05 2009

I Know This

just trying to give you a hard time.

I will eat your babies.....'nuff said.

[peachfuzz]

I will eat your babies.....'nuff said.

[Dancer]

Earlier this month, the first human trials for myostatin inhibitors were published, revealing promising results. The study examined the effects of MYO-029, which is a recombinant human antibody that binds with a high affinity to myostatin and inhibits its activity.3 This myostatin-neutralizing antibody has previously been shown to increase muscle mass in mice by approximately 30 percent over three months.4 The study enrolled 136 subjects with various forms of muscular dystrophy. The subjects were randomized to three groups of MYO-029 dose escalation: group 1 received 1mg/kg; group 2 received 3mg/kg; and group 3 received 10mg/kg. Within each cohort, subjects were randomly assigned to receive the test drug or placebo. MYO-029 was administered intravenously every two weeks for six months (total of 13 doses). After the last dose, subjects were followed for three months. In this first-ever study of a myostatin inhibitor, the primary objective was safety. MYO-029 was well tolerated in the group of people with muscular dystrophies. No target-related side effects were identified to skeletal, smooth, or cardiac muscle. The most significant adverse events reported were skin reactions. Muscle mass was found to increase by approximately 2.4 percent in the 3mg/kg cohort; additionally there was a dose-dependent increase in fiber diameter in the 3 and 10mg/kg groups. The disappointing result of the study was that there were no increases in strength by the myostatin inhibitor. The myostatin drug seemed to have good tolerability at lower dosages, but at higher dosages many subjects experienced adverse skin reactions. The most exciting aspect of the study was that there were no adverse effects on the heart!

-Muscular Development June 05 2009



I will eat your babies.....'nuff said.

http://www.mda.org/research/080311md_myo-029.html

We're disappointed that MYO-029 will not be moving forward," said Sharon Hesterlee, MDA vice president of translational research. "But I doubt this is the end of the line for myostatin inhibition. MDA is looking at other ways to block myostatin and, of course, other strategies to improve muscle health.”

"<Beginning in 2005, with supplemental funding to trial sites from MDA, Wyeth began a phase 1-2 clinical trial to test the safety and tolerability of MYO-029 in 116 adults with Becker, facioscapulohumeral and limb-girdle types of muscular dystrophy.

The compound was found to be safe and well tolerated at three dosage levels, reports a paper published online todayin Annals of Neurology by Kathryn Wagner at Johns Hopkins University School of Medicine in Baltimore, and colleagues.

However, the investigators found no improvements in muscle strength or function, and no statistically significant muscle growth in trial participants. (The authors note that the study was not designed to measure efficacy.)">

[Immortal Soldier]

http://www.mda.org/research/080311md_myo-029.html

We're disappointed that MYO-029 will not be moving forward," said Sharon Hesterlee, MDA vice president of translational research. "But I doubt this is the end of the line for myostatin inhibition. MDA is looking at other ways to block myostatin and, of course, other strategies to improve muscle health.”

"<Beginning in 2005, with supplemental funding to trial sites from MDA, Wyeth began a phase 1-2 clinical trial to test the safety and tolerability of MYO-029 in 116 adults with Becker, facioscapulohumeral and limb-girdle types of muscular dystrophy.

The compound was found to be safe and well tolerated at three dosage levels, reports a paper published online todayin Annals of Neurology by Kathryn Wagner at Johns Hopkins University School of Medicine in Baltimore, and colleagues.

However, the investigators found no improvements in muscle strength or function, and no statistically significant muscle growth in trial participants. (The authors note that the study was not designed to measure efficacy.)">

So basically MYO-029 testing is done, and they are moving towards a new form of myostatin inhibitor.

I am not suprised, since IV injections are bothersome and for a patient to be coming into every 2 weeks is inconvient. I am sure they will find another form of adminstration and a more powerful why to suppress myostatin..

[Dancer]

So basically MYO-029 testing is done, and they are moving towards a new form of myostatin inhibitor.

I am not suprised, since IV injections are bothersome and for a patient to be coming into every 2 weeks is inconvient. I am sure they will find another form of adminstration and a more powerful why to suppress myostatin..

God Even Jerry's kids know that...lol